Critique of world health organization recommendation of a dengue vaccine

Journal of Infectious Diseases

Volumn 214, Issue 12, 2016, Pages 1793-1795

  Halstead, Scott B ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Antibody dependent enhancement (ADE); Dengue vaccine; Dengue virus; Pathogenesis; Safety; Vaccine; Vaccine adverse event

Indexed keywords

DENGUE VACCINE;

DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; NONHUMAN; REVIEW; VACCINATION; WORLD HEALTH ORGANIZATION; ADOLESCENT; CHILD; HOSPITALIZATION; IMMUNOLOGY; INFANT; PRACTICE GUIDELINE; PRESCHOOL CHILD; STATISTICS AND NUMERICAL DATA;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DENGUE; DENGUE VACCINES; HOSPITALIZATION; HUMANS; INFANT; PRACTICE GUIDELINES AS TOPIC; VACCINATION; WORLD HEALTH ORGANIZATION;

EID: 84999770048     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw340     Document Type: Review

References (18)

1. World Health Organization. SAGE meeting of April 2016. http://www. who. int/immunization/ sage/meetings/2016/april/en/. Accessed 22 April 2016.
2. Guy B, Briand O, Lang J, Saville M, Jackson N. Development of the Sanofi Pasteur tetravalent dengue vaccine: one more step forward. Vaccine 2015; 33:7100-11.
3. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012; 380:1559-67.
4. Capeding MR, Tran NH, Hadinegoro SR, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014; 384:1358-65.
5. Villar L, Dayan GH, Arredondo-Garcia JL, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2014; 372:113-23.
6. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 2015; 373:1195-206.
7. SAGE Working Group on Dengue Vaccines and WHO Secretariat. Background paper on dengue vaccines. Geneva: World Health Organization, 2016.
8. Halstead SB, Russell PK. Protective and immunological behavior of chimeric yellow fever dengue vaccine. Vaccine 2016; 34:1643-7.
9. Sanofi Pasteur. Dengvaxia, world's first dengue vaccine, approved in Mexico [news release]. 9 December 2015. http://www. sanofipasteur. com/en/articles/ dengvaxia-world-s-first-dengue-vaccine-approvedin-mexico. aspx. Accessed 24 December 2015.
10. Herriman R. El Salvador becomes the 4th country to approve dengue vaccine. Outbreak News Today. Posted 11 February 2016. http://outbreaknewstoday. com/ el-salvador-becomes-the-4th-country-to-approvedengue-vaccine-53510/. Accessed 14 February 2016.
11. Maron DF. First dengue fever vaccine gets green light in 3 countries. Scientific American. 30 December 2015. http://www. scientificamerican. com/ article/first-dengue-fever-vaccine-gets-green-lightin-three-countries/. Accessed 5 January 2016.
12. Coudeville L, Baurin N, Vergu E. Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies. Vaccine 2016; In press.
13. Velumani S, Toh YX, Balasingam S, et al. Low antibody titers 5 years after vaccination with the CYD-TDV dengue vaccine in both pre-immune and naive vaccinees. Hum Vaccin Immunother 2016; 12:1265-73.
14. Halstead SB. Neutralization and antibody dependent enhancement of dengue viruses. Adv Virus Res 2003; 60:421-67.
15. Guzman MG, Kouri G, Bravo J, Valdes L, Vazquez SHalstead SB. Effect of age on outcome of secondary dengue 2 infections. Intern J Infect Dis 2002; 6:118-24.
16. Anders KL, Nguyet NM, Chau NV, et al. Epidemiological factors associated with dengue shock syndrome and mortality in hospitalized dengue patients in Ho Chi Minh City, Vietnam. Am J Trop Med Hyg 2011; 84:127-34.
17. Guzman MG, Kouri GP, Bravo J, Soler M, Vazquez SMorier L. Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am J Trop Med Hyg 1990; 42:179-84.
18. Guzman MG, Kouri G, Valdes L, Bravo J, Vazquez SHalstead SB. Enhanced severity of secondary dengue 2 infections occurring at an interval of 20 compared with 4 years after dengue 1 infection. PAHO J Epidemiol 2002; 81:223-7.